Evidence map›Paper›PMID 42209454›Full record

ArticleBlood cancer journal2026

Long-term outcomes of low-dose dasatinib in older patients with chronic myeloid leukemia in chronic phase: an extended follow-up of the DAVLEC phase 2 trial.

Hiroshi Ureshino, Kazunori Murai, Takashi Kumagai, Tatsuji Mino, Kaichi Nishiwaki, Satoshi Wakita, Tomoharu Takeoka, Masayuki Mita, Chikashi Yoshida, Nobuhiko Uoshima and 14 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Road to treatment-free remission in chronic myeloid leukemia.International journal of hematology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors.

Hiroshi UreshinoDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan. sr0795@cc.saga-u.ac.jp.ORCID http://orcid.org/0000-0002-5034-3699
Kazunori MuraiDepartment of Hematology, Iwate Prefectural Central Hospital, Morioka, Japan.
Takashi KumagaiDepartment of Hematology, Ome Medical Center, Ome, Japan.
Tatsuji MinoDepartment of Hematology, Hiroshima City Asa Hospital, Hiroshima, Japan.
Kaichi NishiwakiDivision of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University Kashiwa Hospital, Kashiwa, Japan.
Satoshi WakitaDepartment of Hematology, Nippon Medical School, Tokyo, Japan.
Tomoharu TakeokaDivision of Hematology and Immunology, Japanese Red Cross Otsu Hospital, Otsu, Japan.
Masayuki MitaDepartment of Hematology, Shirakawa Kosei General Hospital, Shirakawa, Japan.
Chikashi YoshidaDepartment of Hematology, National Hospital Organization Mito Medical Center, Ibaraki, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Toshihiro FukushimaDepartment of Hematology and Immunology, Kanazawa Medical University, Kanazawa, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.ORCID http://orcid.org/0000-0001-6130-1550
Takeshi KondoBlood Disorders Center, Aiiku Hospital, Sapporo, Japan.ORCID http://orcid.org/0000-0001-7455-5824
Masahiro ChibaDepartment of Hematology, Asahikawa City Hospital, Asahikawa, Japan.
Takuya MiyazakiDepartment of Hematology, Yokohama City University Medical Center, Yokohama, Japan.ORCID http://orcid.org/0000-0003-1884-4757
Katsuhiro IoDepartment of Hematology, Kansai Electric Power Hospital, Osaka, Japan.
Tomoaki UedaDepartment of Hematology and Oncology, The University of Osaka, Suita, Japan.
Takaaki OnoDivison of Hematology, Hamamatsu University School of Medicine, Hamamatsu, Japan.
Kensuke UsukiForth Department of Internal Medicine, Mizonokuchi Hospital, Teikyo University School of Medicine, Itabashi City, Japan.ORCID http://orcid.org/0000-0002-1216-4470
Takahiro YamauchiDepartment of Hematology and Oncology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.ORCID http://orcid.org/0000-0002-6531-812X
Katsumichi FujimakiDepartment of Hematology, Fujisawa City Hospital, Fujisawa, Japan.
Takayuki IkezoeDepartment of Hematology, Fukushima Medical University, Fukushima, Japan.ORCID http://orcid.org/0000-0002-7858-278X
Atsushi KawaguchiEducation and Research Center for Community Medicine, Faculty of Medicine, Saga University, Saga, Japan.
Shinya KimuraDivision of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan.ORCID http://orcid.org/0000-0003-1717-6208

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID42209454
PMCPMC13219402

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.